Sernova – Patentierte Zelltaschen mit Schutzschild gegen die Immunabwehr ! (Seite 2)
eröffnet am 24.06.15 16:59:24 von
neuester Beitrag 31.05.24 20:50:58 von
neuester Beitrag 31.05.24 20:50:58 von
Beiträge: 8.633
ID: 1.214.676
ID: 1.214.676
Aufrufe heute: 13
Gesamt: 1.085.672
Gesamt: 1.085.672
Aktive User: 0
ISIN: CA81732W1041 · WKN: A0LBCR · Symbol: SVA
0,2435
EUR
+8,46 %
+0,0190 EUR
Letzter Kurs 31.05.24 L&S Exchange
Neuigkeiten
| TitelBeiträge |
|---|
30.05.24 · Shareribs Anzeige |
29.05.24 · wO Chartvergleich |
28.05.24 · Shareribs Anzeige |
28.05.24 · IRW Press |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,4900 | +185,09 | |
| 1,0500 | +128,31 | |
| 0,9899 | +41,41 | |
| 0,8600 | +41,22 | |
| 3,3000 | +15,99 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,4350 | -18,47 | |
| 5,5100 | -18,97 | |
| 1,5000 | -25,00 | |
| 0,9000 | -53,85 | |
| 0,6002 | -57,27 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 75.852.410 von XC_2011 am 28.05.24 15:58:54Wird sie , zu 100 Prozent bin ich mir sicher
Antwort auf Beitrag Nr.: 75.851.096 von marvessa am 28.05.24 12:33:07
Ob sie kauft wird sich dann zeigen!
Zitat von marvessa: Wann ist black period zu Ende damit Cathy kaufen darf ?
Ob sie kauft wird sich dann zeigen!
Black periode ist für Aktionäre schon länger.....
Wann ist black period zu Ende damit Cathy kaufen darf ?
Trading Spotlight
Press Release - May 28, 2024
Sernova Appoints Jonathan Rigby to its Board of Directors
Sernova Appoints Jonathan Rigby to its Board of Directors
LONDON, Ontario; BOSTON, Massachusetts – May 28, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, announces today that Jonathan Rigby will join Sernova’s Board of Directors effective immediately.
“We are excited to welcome Jonathan to Sernova’s Board of Directors. With more than 30 years of diverse experience across the biopharmaceutical landscape, Jonathan brings a track record of substantial contributions across our sector as a biotech CEO and Board member. He will both complement and augment the expertise and composition of our current Board,” said Cynthia Pussinen, Chief Executive Officer of Sernova. “We welcome Jonathan’s passion for improving the lives of patients and his guidance on accelerating delivery of our development programs.”
Mr. Rigby has a breadth of industry knowledge and productive experience having served as President and CEO of Revolo Biotherapeutics where he took the company through multiple financings and two Phase 2 clinical trials, as well as serving as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS), with an oversold IPO. Mr. Rigby served as the CEO for SteadyMed Therapeutics (NASDAQ: STDY), which he listed on Nasdaq prior to its acquisition by United Therapeutics (NASDAQ: UTHR), and was co-founder of Zogenix (NASDAQ:ZGNX), which was also acquired by UCB (Euronext: UCB) after completing a NASDAQ listing.
In addition, Mr. Rigby currently serves on the Board of Directors of cancer therapy company Oncolytics Biotech Inc. (NASDAQ: ONCY) and IM Therapeutics which is developing therapies for Type 1 diabetes (T1D). He is a past Board Member of Thermalin Inc., which engineered new forms of insulin to improve patient lives and outcomes for the treatment of T1D and was formerly on the board of Xeris Pharmaceuticals (NASDAQ: XERS) which developed and commercialised a therapy to treat T1D severe hypoglycemia. Mr. Rigby holds a degree in Biological Sciences from the University of Sheffield, UK, and has a Master of Business Administration degree from the University of Portsmouth, UK.
“As an individual with T1D, I am acutely aware of the challenges of living with this life changing condition and the need to effectively cure the disease. Given Sernova’s vision of a future where chronic conditions are no longer insurmountable obstacles, and their foundational work on delivering a ‘functional cure’ for T1D, I am especially excited to join the Board and work hard to progress the company forward. Sernova represents a new era of development for cell therapy treatments and I look forward to working with the Board and the leadership team in advancing Sernova’s groundbreaking technology and therapies,” said Mr. Rigby.
Sernova Appoints Jonathan Rigby to its Board of Directors
Sernova Appoints Jonathan Rigby to its Board of Directors
LONDON, Ontario; BOSTON, Massachusetts – May 28, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, announces today that Jonathan Rigby will join Sernova’s Board of Directors effective immediately.
“We are excited to welcome Jonathan to Sernova’s Board of Directors. With more than 30 years of diverse experience across the biopharmaceutical landscape, Jonathan brings a track record of substantial contributions across our sector as a biotech CEO and Board member. He will both complement and augment the expertise and composition of our current Board,” said Cynthia Pussinen, Chief Executive Officer of Sernova. “We welcome Jonathan’s passion for improving the lives of patients and his guidance on accelerating delivery of our development programs.”
Mr. Rigby has a breadth of industry knowledge and productive experience having served as President and CEO of Revolo Biotherapeutics where he took the company through multiple financings and two Phase 2 clinical trials, as well as serving as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS), with an oversold IPO. Mr. Rigby served as the CEO for SteadyMed Therapeutics (NASDAQ: STDY), which he listed on Nasdaq prior to its acquisition by United Therapeutics (NASDAQ: UTHR), and was co-founder of Zogenix (NASDAQ:ZGNX), which was also acquired by UCB (Euronext: UCB) after completing a NASDAQ listing.
In addition, Mr. Rigby currently serves on the Board of Directors of cancer therapy company Oncolytics Biotech Inc. (NASDAQ: ONCY) and IM Therapeutics which is developing therapies for Type 1 diabetes (T1D). He is a past Board Member of Thermalin Inc., which engineered new forms of insulin to improve patient lives and outcomes for the treatment of T1D and was formerly on the board of Xeris Pharmaceuticals (NASDAQ: XERS) which developed and commercialised a therapy to treat T1D severe hypoglycemia. Mr. Rigby holds a degree in Biological Sciences from the University of Sheffield, UK, and has a Master of Business Administration degree from the University of Portsmouth, UK.
“As an individual with T1D, I am acutely aware of the challenges of living with this life changing condition and the need to effectively cure the disease. Given Sernova’s vision of a future where chronic conditions are no longer insurmountable obstacles, and their foundational work on delivering a ‘functional cure’ for T1D, I am especially excited to join the Board and work hard to progress the company forward. Sernova represents a new era of development for cell therapy treatments and I look forward to working with the Board and the leadership team in advancing Sernova’s groundbreaking technology and therapies,” said Mr. Rigby.
Ich habe nie behauptet, ein Wissenschaftler zu sein und alles genau zu verstehen.
Der Investmentcase bei sernova war aber die funktionale Heilung von Diabetes durch die Zelltasche.
Diese funktionale Heilung funktioniert halt ( noch ) nicht , wie versprochen ohne zusätzliche Medikamente.
Andere Probleme bestehen wohl auch noch ( Durchblutung).
Daher ist derzeit nicht erkennbar, wo die Reise hingeht.
Der Investmentcase bei sernova war aber die funktionale Heilung von Diabetes durch die Zelltasche.
Diese funktionale Heilung funktioniert halt ( noch ) nicht , wie versprochen ohne zusätzliche Medikamente.
Andere Probleme bestehen wohl auch noch ( Durchblutung).
Daher ist derzeit nicht erkennbar, wo die Reise hingeht.
Ich erwarte diese Woche eine News. Morgen oder spätistens Mittwoch
Antwort auf Beitrag Nr.: 75.844.523 von Ghost-Cash am 27.05.24 10:46:10Das waren keine beleidigende Worte, sondern eine Richtigstellung falscher Aussagen.
Durchsuchen
Sernova – Patentierte Zelltaschen mit Schutzschild gegen die Immunabwehr !
